Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 84

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 84
---
 it maintains sufficient cash balances to meet its existing and reasonably likely long-term
liquidity needs.

NewGenIvf intends to finance
its future working capital requirements and capital expenditures from cash generated from operating activities, in addition to funds raised
from financing activities. NewGenIvf may, however, require additional cash due to changing business conditions or other future developments,
including any investments or acquisitions it may decide to pursue. If its existing cash is insufficient to meet its requirements, NewGenIvf
may seek to issue debt or equity securities or obtain additional credit facilities. Financing may be unavailable in the amounts NewGenIvf
needs or on terms acceptable to it, if at all. Issuance of additional equity securities, including convertible debt securities, would
dilute NewGenIvf’s earnings per share. The incurrence of debt would divert cash for working capital and capital expenditures to
service debt obligations and could result in operating and financial covenants that restrict NewGenIvf’s operations and its ability
to pay dividends to its shareholders. If NewGenIvf is unable to obtain additional equity or debt financing as required, its business operations
and prospects may suffer. Please see “ Risk Factors - Risks Relating to NewGenIvf’s Business and Industry - 
NewGenIvf requires a significant amount of capital to fund its operations and growth. If NewGenIvf cannot obtain sufficient capital on
acceptable terms, its business, financial condition, and prospects may be materially and adversely affected.”

The following table presents
NewGenIvf’s selected consolidated cash flow data for the periods indicated.

                                                                           For the Year ended                                  
                                                                           December 31,                                        
                                                                           2024                                                
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                           US$                                                 
  Net cash used in operating activities                                                            (8,264,074      (1,766,135  
  Net cash used in investing activities                                                               (53,045         (69,848  
  Net cash provided by financing activities                                                         8,675,790       1,881,493  
  Net increase in cash and cash equivalents                                                           358,671          45,510  
  Effect of foreign currency translation on cash and cash equivalents                                  44,965         (18,962  
  Cash and cash equivalents, beginning of year                                                         54,104          27,556  
  Cash and cash equivalents, end of year                                                              457,740          54,104